Clinical Research
Curative effect of desloratadine citrate combined with budesonide in patients with sinusitis
Chen Xuesong, Wang Xuesong, Fu Weiwei
Published 2021-07-15
Cite as IMHGN, 2021, 27(14): 2170-2173. DOI: 10.3760/cma.j.issn.1007-1245.2021.14.032
Abstract
ObjectiveTo investigate the curative effect of desloratadine citrate combined with budesonide in patients with sinusitis.
MethodsA total of 86 patients with sinusitis in our hospital from February 2018 to February 2020 were selected and were divided into a study group and a control group with the random number table, 43 cases in each group. In the control group, there were 25 males and 18 females, with an age of (38.4±1.2) years old; in the study group, there were 26 males and 17 females, with an age of (38.3±1.3) years old. The control group was treated with budesonide, and the study group was treated with desloratadine citrate combined with budesonide. The curative effects, allergic reactions, and inflammatory factors of the two groups were observed and analyzed.
ResultsThe total effective rate of the study group was 93.0% (40/43), which was significantly higher than 65.1% (28/43) of the control group (χ2=10.118, P<0.05). Before the treatment, there were no statistically significant differences in the allergic reactions of sinusitis patients between the two groups (bothP>0.05); after the treatment, serum total immunoglobulin E (TIgE) and eosinophilic cationic protein (ECP) levels of the study group were (56.3±4.2) kU/L and (4.1±0.3) ng/L respectively, which were significantly lower than those of the control group [(64.2±6.9) kU/L and (5.5±0.9) ng/L] (bothP<0.05). Before the treatment, there were no statistically significant differences in the levels of inflammatory factors between the two groups (allP>0.05); after the treatment, serum levels of interleukin (IL)-6, high-sensitivity C-reactive protein (hs-CRP), and tumor necrosis factor (TNF)-α in the study group were (1.2±0.4) μg/L, (5.2±1.1) pg/ml, and (2.8±0.3) ng/L, respectively, which were lower than those in the control group [(2.8±0.8) μg/L, (10.3±2.1) pg/ml, and (3.9±0.7) ng/L] (allP<0.05).
ConclusionThe application of desloratadine citrate combined with budesonide in the treatment of patients with sinusitis can effectively enhance the therapeutic effect, significantly reduce the serum TIgE and ECP levels of patients, and inhibit the inflammatory reaction to a certain extent, which can be widely used.
Key words:
Desloratadine citrate; Budesonide; Sinusitis; Clinical efficacy; Total immunoglobulin E; Eosinophilic cationic protein
Contributor Information
Chen Xuesong
E.NT. Department, Binzhou Central Hospital, Binzhou 251700, China
Wang Xuesong
E.NT. Department, Binzhou Central Hospital, Binzhou 251700, China
Fu Weiwei
E.NT. Department, Binzhou Central Hospital, Binzhou 251700, China
